Connect with us

Business

States give marijuana data to Biden administration for rescheduling review

Published

on

At least five states with medical marijuana programs have shared key data – including the products patients are using and how they are affected – with U.S. health regulators as part of the Biden administration’s review of whether to remove marijuana from the federal government’s list of the most dangerous drugs, MJBizDaily has learned.

The state data sent to the U.S. Food and Drug Administration and the Department of Health and Human Services (HHS) offers federal researchers a wider and deeper look into marijuana use and its medical potential than most peer-reviewed studies available to researchers, experts told MJBizDaily.

In sharing the data, officials hope to influence the ongoing federal review of cannabis’ status under the Controlled Substances Act (CSA), which still serves as an immovable barrier to long-awaited federal marijuana reform, including interstate commerce and tax relief.

President Joe Biden ordered the review last fall.

The process ultimately could lead to lower federal taxes for cannabis companies and better access to traditional financial services as well as legal interstate commerce and, possibly, federal marijuana legalization – although the final outcome is far from clear.

So far, Illinois, Maryland, Massachusetts, Minnesota and Utah have shared information with federal health regulators about marijuana use gleaned from their state programs, officials from those markets confirmed.

“This is going to be some of the most important data considered,” predicted Jahan Marcu, a published researcher who earned a Ph.D. examining the endocannabinoid system and is serving as scientific adviser to the Coalition for Cannabis Scheduling Reform (CCSR).

The CCSR is a collection of major multistate operators seeking to encourage rescheduling or descheduling marijuana.

States shared the insight into marijuana use and MJ products at the encouragement of the Cannabis Regulators Association, an organization comprised of government officials overseeing state programs.

The revelation that states are participating in the administrative rescheduling review offers a rare peek into that process, which federal health officials have kept a near secret so far, observers in Congress and on Capitol Hill said.

Asked previously what studies or data officials are weighing, spokespeople for the federal health agencies have declined to elaborate.

Separately, a spokesperson from the U.S. Food and Drug Administration did not respond to an MJBizDaily request for comment this week.

“So much money has been put into understanding the risks of illicit cannabis,” Marcu noted.

By comparison, there’s been very little research into legal commercial marijuana.

“With state-level data, you’re talking about what products people are using, any health effects – that information is so important,” he added. “In some ways, that’s what Big Pharma does.”

Surveys say

“We shared a subset of our data – minus any identifying information – with the FDA,” David Rak, the research manager at the Minnesota Department of Public Health’s Office of Medical Cannabis, told MJBizDaily via email.

“We collect data from our patients every time they go to make a purchase at a dispensary (Patient Self Evaluation), and offer an optional survey at fixed intervals (Patient Experience Survey).

“So, we have a fair amount of data to analyze.”

Minnesota’s data also includes reports of adverse events, such as prescription-drug interactions.

“In general, we’ve had very few adverse events reported,” Rak said.

According to Rak, the FDA has yet to respond to the states that shared information.

Massachusetts officials “submitted data and information to the U.S. Food and Drug Administration as part of its review of cannabis’s scheduling status, including conditions approved for medicinal cannabis use, cannabinoid profiles of medical-use products, and frequency and quantity of medical patient purchases from the medical-use market,” a spokesperson for the state Cannabis Control Commission told MJBizDaily via email.

“We look forward to continuing to work with our partners at the state and federal level to encourage additional research and data-sharing, and ultimately impact nationwide policy.”

Unique source

In an ongoing paradox that Congress has yet to untangle, current federal drug laws thwart and discourage research into cannabis.

The marijuana research bill that Biden signed into law last fall – drafted by one of the country’s most prominent anti-legalization organizations – has not yielded new research protocols nor new sources of research-grade cannabis.

Critics have told MJBizDaily that the research bill is failing by design.

Meanwhile, federal officials have repeatedly said more research is necessary before marijuana prohibition can be weakened or undone.

The little marijuana research that does go on in the U.S. typically examines cannabis grown by U.S. Drug Enforcement Administration-approved suppliers.

Experts agree this supply does not bear much resemblance to the marijuana available in state-legal medical dispensaries.

When determining a drug’s appropriate classification under the CSA, the FDA employs what’s called an “eight-factor analysis.”

The eight factors considered are:

In another demonstration of how marijuana’s legal status stymies research that could change that status, there are a limited number of peer-reviewed academic studies that the FDA would traditionally rely on for the eight-factor analysis process, said Gillian Schauer, executive director of the Cannabis Regulators Association.

“A number of state medical cannabis programs have rich data sources around patient use of cannabis, clinical recommendations for medical cannabis, adverse events (or lack thereof), and more,” she said via email.

“These data are typically not collected for academic or research purposes but rather for consumer safety, program improvement, and regulatory reasons.”

Those states that haven’t yet shared data are encouraged to do so, Schauer added.

“It is imperative that these data are shared with the FDA so they can conduct the 8-factor analysis with data not only from academia, but from what is happening in practice on the ground in states and territories.”

‘Nobody can really say’

In announcing his administration’s rescheduling review last October, Biden noted in a statement that federal law “currently classifies marijuana in Schedule 1 of the Controlled Substances Act, the classification meant for the most dangerous substances.

“This is the same schedule as for heroin and LSD, and even higher than the classification of fentanyl and methamphetamine – the drugs that are driving our overdose epidemic.”

For most laypeople as well as Biden – and many lawmakers and officials who have decried the conflict between state and federal MJ laws as well as the Nixon-era declaration that marijuana is more dangerous than heroin – the idea that cannabis should be reclassified from Schedule 1 is obvious.

Schedule 1 is the category reserved for drugs with a high potential for abuse and no medical value.

Less obvious is how far federal health officials will go in their recommendation, which is due to the DEA by the end of the year, and whether law enforcement officials will take heed.

“What nobody can really say is what the scientists (at the FDA and HHS) are going to look at and what will be persuasive,” said Andrew Freedman, a senior vice president at influential Washington DC-based law and lobbying firm Forbes Tate and the executive director of the Coalition for Cannabis Policy, Education, and Regulation.

That’s also true of scientific studies. “How persuasive they will find anecdotes at the state level, I think, will be harder to determine,” Freedman added.

“The other thing that’s going to confuse this analysis is, well, what ‘cannabis’ are we talking about?” he added.

“Are we talking about someone who uses shatter three times a day, or someone who smokes half a joint with a friend on a Friday night?

“Those are two different versions of risk. Cannabis is not one thing, even though it’s scheduled as one thing.”

Most experts agree that health officials are unlikely to remove marijuana from the Controlled Substances Act entirely.

That might satisfy some major cannabis companies, as the notorious Section 280E of the federal tax code – which bars marijuana operators from taking basic deductions for business expenses – does not apply to drugs classified Schedule 3 or lower.

But it won’t satisfy advocates or many regulators, whose state frameworks aren’t set up for drugs controlled at that level, which are typically sold at pharmacies.

“This data is going to be used to support some sort of showing that there is a medical benefit,” said Griffen Thorne, a Los Angeles-based attorney at Harris Bricken.

“Everybody knows there is some medical benefit, at least for pain if for nothing else.”

But will that convince federal regulators? It’s still anyone’s guess.

“It’s hard to deduce what the federal government is doing,” Thorne noted.

Source: https://mjbizdaily.com/states-give-marijuana-data-to-biden-administration-for-rescheduling-review/

Business

Jio’s 1,600-Satellite LEO Constellation Gets Technical Green Light

Published

on

By

Reliance Jio has crossed a significant milestone in its space connectivity ambitions after its proposal to deploy a Low Earth Orbit (LEO) satellite constellation of around 1,600 satellites received a positive technical assessment from the Indian National Space Promotion and Authorisation Centre (IN-SPACe).

The evaluation, conducted jointly by IN-SPACe, the Indian Space Research Organisation (ISRO), and the Wireless Planning and Coordination (WPC) wing of the Department of Telecommunications, reportedly concluded that Jio’s proposed system meets the required technical standards and is comparable to leading global satellite broadband networks.

India’s Indigenous LEO Satellite Vision

Under the proposal, Reliance Jio plans to deploy between 1,600 and 1,650 satellites in Low Earth Orbit at an altitude of around 650 kilometres.

The planned constellation is expected to provide high-speed satellite connectivity across India, with approximately 32 satellites visible from any location at a given time. The company aims to roll out the network within the next two to three years, subject to regulatory approvals.

According to industry estimates, the satellite system could deliver 4.5 to 5 terabits per second (Tbps) of total data capacity, making it one of the largest satellite broadband projects proposed in India.

The project is expected to require an investment of $10–15 billion (approximately ₹95,000 crore to ₹1.42 lakh crore), reflecting the scale of infrastructure needed for satellite manufacturing, launches, ground stations, and user terminals.

Regulatory Process Moves Forward

Following the successful technical review, the proposal is expected to move into the next phase of regulatory approvals.

The government may now assist Jio in securing orbital slots, coordinating spectrum usage, and filing applications with the International Telecommunication Union (ITU), the global body responsible for managing satellite orbit and frequency allocations.

Obtaining orbital rights remains a critical step, as Low Earth Orbit has become increasingly competitive due to the growing number of satellite broadband projects being planned worldwide.

Officials also indicated that the proposed satellite architecture has been designed to coexist with future Indian LEO constellations, allowing multiple domestic operators to share orbital resources efficiently.

Broadband, Mobile Connectivity, and Strategic Applications

Jio plans to use the satellite network to provide a range of communication services, including satellite broadband, mobile backhaul, enterprise connectivity, and direct-to-device (D2D) satellite communication, particularly in remote and underserved regions where conventional telecom infrastructure is limited.

The company also intends to establish 20 to 22 ground stations across India to support network operations.

Apart from commercial telecommunications, officials have highlighted the project’s potential strategic importance. A domestically developed satellite constellation could strengthen India’s communication infrastructure, reduce dependence on foreign satellite operators, and support national security requirements.

Reports suggest preliminary discussions are underway regarding the possibility of integrating defence-related payloads into some satellites, enabling both civilian and strategic use.

Major Step for India’s Space and Telecom Sectors

Industry analysts view the technical clearance as an important milestone in India’s expanding private space ecosystem. If Jio secures the remaining regulatory approvals and international orbital clearances, the project could become the country’s first large-scale indigenous LEO satellite broadband network.

The initiative also aligns with India’s broader efforts to expand digital connectivity while strengthening its presence in the global satellite communications market.

Continue Reading

Business

Alleged Crores Pharma Scam Mastermind Arrested from Surat

Published

on

By

After evading law enforcement for nearly 13 years, an accused linked to a large-scale pharmaceutical fraud case has been arrested by Delhi Police from Surat, Gujarat. The suspect is alleged to have orchestrated a series of financial scams involving fake identities, forged documents, and dishonoured cheques used to procure high-value pharmaceutical raw materials.

Authorities say the accused, identified as Himmat Singh Lodha, is believed to have defrauded multiple pharmaceutical companies in Delhi of goods worth approximately ₹98 lakh before disappearing and remaining underground for years.

Fake Business Deals and Dishonoured Cheques Used in Fraud

Investigators claim the accused posed as a legitimate pharmaceutical trader and placed bulk orders for expensive drug ingredients, offering post-dated cheques as payment security.

In one documented case from 2013, he allegedly obtained around 550 kilograms of Gliclazide, a diabetes-related pharmaceutical ingredient, valued at over ₹26 lakh. When suppliers attempted to encash the cheques, they were reportedly returned with the remark “account closed.”

Following the transaction, the accused allegedly vacated his office and rented residence and disappeared without settling payments. He was later declared a proclaimed offender in 2016 after repeatedly failing to appear before court proceedings. Authorities had also issued a reward for information leading to his arrest.

Multiple Identities and Repeated Fraud Pattern

Police investigations further link the accused to another cheating case dating back to 2012, where he allegedly used a fake identity, “Kailash Jain,” to obtain a large consignment of Ambroxol HCL, a pharmaceutical compound used in cough medications. The value of that consignment was estimated at around ₹72 lakh.

Officials believe the accused followed a consistent modus operandi—posing as a credible businessman, securing high-value goods on deferred payment terms, and then disappearing after delivery while shutting down business operations.

Investigators suspect that forged business records, fake company credentials, and fabricated financial histories were used to build trust with suppliers and gain access to expensive raw materials.

Multi-State Surveillance Leads to Arrest in Surat

A special Crime Branch team tracked the accused through coordinated surveillance efforts across multiple cities, including Mumbai, Ahmedabad, and Surat. After nearly a month of technical monitoring and intelligence gathering, officials located and arrested him from a residential area in Surat.

Authorities also revealed that the accused had been involved in property-related activities while staying under the radar to avoid detection.

Growing Threat of Corporate Identity Fraud

The case highlights a rising trend of organised financial fraud targeting industries that rely heavily on trust-based transactions and deferred payments. Experts note that criminals increasingly exploit gaps in corporate verification systems by using fake GST registrations, temporary offices, and forged documentation to appear legitimate.

Cybercrime and financial fraud specialists warn that such schemes are becoming more complex with the widespread availability of digital business tools, making it easier to create convincing but fraudulent corporate identities.

Experts Urge Stronger Due Diligence in High-Value Transactions

Experts, including former IPS officer and cybercrime specialist Prof. Triveni Singh, emphasize the need for stricter verification procedures in commercial dealings. He noted that relying solely on paperwork or digital business profiles can expose companies to significant financial risk.

Authorities and industry experts recommend physical verification of business operations, bank account validation, and detailed background checks before engaging in high-value or deferred-payment transactions—particularly in sectors like pharmaceuticals, where single consignments can involve transactions worth crores.

Continue Reading

Business

EU Pressure Builds on Google as Regulators Face Calls for Massive Fine Over Search Practices

Published

on

By

A growing coalition of European industry groups is intensifying pressure on regulators to take decisive action against Google over allegations of unfair search practices that could reshape competition rules across the region’s digital economy.

Investigation Under Digital Markets Act Gains Momentum

The case is being examined by the European Commission under the European Union’s landmark Digital Markets Act (DMA), introduced to curb the dominance of major technology platforms and ensure fair competition.

Launched in March 2024, the investigation focuses on whether Google has been prioritising its own services in search results, potentially disadvantaging rival businesses that rely on online visibility to reach customers.

Industry Groups Demand Swift Action

Several prominent European organizations have jointly urged regulators to conclude the probe without further delay. They argue that prolonged investigations allow alleged anti-competitive practices to continue, putting European companies—especially startups—at a disadvantage.

Signatories include the European Publishers Council, the European Magazine Media Association, the European Tech Alliance, and EU Travel Tech.

In a joint statement, these groups warned that delays in enforcement are affecting innovation, profitability, and growth prospects for regional businesses competing in digital markets.

Google Denies Allegations

Google has rejected claims of bias, stating that its search algorithms are designed to deliver the most relevant and useful results to users. The company has also proposed adjustments to address regulatory concerns.

However, critics argue that these changes are insufficient and fail to address the core issue of market dominance.

Potential Billion-Euro Penalties

If found in violation of the DMA, Google could face significant financial penalties. Under EU rules, fines can reach a substantial percentage of a company’s global turnover, potentially amounting to billions of euros.

Regulators may also impose corrective measures requiring changes to business practices, which could have long-term implications for how digital platforms operate in Europe.

Wider Implications for Big Tech

The case highlights ongoing tensions between European regulators and major U.S. technology firms. In recent years, the EU has taken a more aggressive stance in enforcing competition laws, aiming to create a level playing field for local businesses.

A final ruling against Google could set a major precedent, influencing future enforcement actions and shaping the regulatory landscape for global tech companies operating within Europe.

As scrutiny intensifies, the outcome of the investigation is expected to play a critical role in defining the future of digital competition across the European Union.

Continue Reading

Trending

Copyright © 2022 420 Reports Marijuana News & Information Website | Reefer News | Cannabis News